<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11947">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00530790</url>
  </required_header>
  <id_info>
    <org_study_id>107846</org_study_id>
    <nct_id>NCT00530790</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Ropinirole CR-RLS ( SK&amp;F101468)Tablets in Restless Legs Syndrome</brief_title>
  <official_title>Clinical Evaluation of Ropinirole CR-RLS Tablets in Restless Legs Syndrome-Open-Label, Uncontrolled Study. Classification: Clinical Pharmacology, Exploratory</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to evaluate the safety, pharmacokinetic profile and efficacy in
      Restless Legs Syndrome patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Drug Related Adverse Events-On-Therapy</measure>
    <time_frame>Weeks 1 - 12 Treatment Period</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Haematology Clinical Lab Values Change From Baseline</measure>
    <time_frame>Baseline - Week 13 (Follow-up)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Standard units of measure vary. Therefore, Mean Change is represented in Standard Units: Hematocrit = SI unit of GSK; Hemoglobin = G/L; Platelet count, White Blood Cell count = GI/L; Red Blood Cell count = TI/L. n = number of subjects evaluated. EW = Early Withdrawal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Chemistry Clinical Lab Values Change From Baseline</measure>
    <time_frame>Baseline - Week 13 (Follow-up)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean Change in Standard Units of Measure: Albumin, Total Protein=G/L; Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Lactate Dehydrogenase, Creatine Phosphokinase, Gamma Glutamyl Transferase=IU/L; Total Bilirubin, Creatinine=UMOL/L; Blood Urea Nitrogen, Cholesterol, Chloride, Sodium, Potassium=MMOL/L; Prolactin=MCG/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinalysis Clinical Lab Values</measure>
    <time_frame>Baseline - Week 13 (Follow-up)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Dipstick test values: Neg Value, Trace, +1, +2, +3. No subjects tested higher than +3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12-Lead Electrocardiogram (ECG) Findings Transitions From Baseline</measure>
    <time_frame>Baseline, Week 4, 8, 12, 13 (Follow-up)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Baseline Finding/Time Period Finding. Abbreviations: N = normal; A = abnormal; CS = clinically significant; NCS = not clinically significant. Options include N/N, N/ANCS, N/ACS, ANCS/N, ANCS/ANCS, ANCS/ACS, ACS/N, ACS/ANCS, and ACS/ACS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs and Body Weight Change From Baseline</measure>
    <time_frame>Baseline to Week 12/EW</time_frame>
    <safety_issue>No</safety_issue>
    <description>Units of Measure Vary: Weight = kg; Semi-supine and Standing Systolic and Diastolic BP = mmHg; Semi-supine and Standing Pulse Rate = bpm; EW = early withdrawal; Semi-supine = lying down; Orthostatic = lying, sitting, and standing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in International Restless Leg Syndrome (IRLS) Rating Scale Total Score</measure>
    <time_frame>Baseline and after Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The IRLS Scale assesses the severity of sensory and motor symptoms, sleep disturbance, daytime somnolence, and impact on activities of daily living and mood. The questionnaire scores various questions and totals them using the following scale: Very severe=31-40 points, Severe=21-30 points, Moderate=11-20 points, Mild=1-10 points, None=0 points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Scale - Severity of Illness (CGI-S)</measure>
    <time_frame>Baseline - Final assessment point</time_frame>
    <safety_issue>No</safety_issue>
    <description>The CGI-S scale measures the overall severity of illness on a 7 point scale. Normal = 1, Borderline = 2, Mildly = 3, Moderately = 4, Markedly = 5, Severely = 6, Extremely Severe = 7(no subjects scored a 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Global Improvement (CGI-GI)</measure>
    <time_frame>Baseline - Final assessment point</time_frame>
    <safety_issue>No</safety_issue>
    <description>CGI-GI is a 7 point scale assessing Global Improvement. 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse (no patients scored a 5, 6, or 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at Week 12/Early Withdrawal (EW) in Pittsburgh Sleep Quality Index (PSQI) Total Score</measure>
    <time_frame>Baseline - Week 12/EW</time_frame>
    <safety_issue>No</safety_issue>
    <description>The PSQI generates seven scores that correspond to different domains. Each component score ranges from 0 (no difficulty) to 3 (severe difficulty). The domain scores are totaled to produce a global score (range of 0-21). A PSQI global score &gt; 5 is considered to be suggestive of significant sleep disturbance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12/EW in Pittsburgh Sleep Quality Index (PSQI) Total Score by Domains</measure>
    <time_frame>Baseline - Week 12/EW</time_frame>
    <safety_issue>No</safety_issue>
    <description>The PSQI generates seven scores that correspond to different domains. Each component score ranges from 0 (no difficulty) to 3 (severe difficulty). The domain scores are totaled to produce a global score (range of 0-21). A PSQI global score &gt; 5 is considered to be suggestive of significant sleep disturbance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at Week 12/Early Withdrawal (EW) in Johns Hopkins Restless Leg Syndrome Quality of Life Questionnaire (RLSQOL) on the Overall Life Impact Score</measure>
    <time_frame>Baseline and Week 12/EW</time_frame>
    <safety_issue>No</safety_issue>
    <description>The RLSQOL scale consists of 18 items, 13 of which are scored on a 5-point scale. Ten of the items can be summed to the overall life impact score, which can be transformed to a 0-100 score. Mild = 84.48, Moderate = 62.93, or Severe = 37.47</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at Week 12/Early Withdrawal (EW) in Profile of Mood Status (POMS)</measure>
    <time_frame>Baseline and Week 12/EW</time_frame>
    <safety_issue>No</safety_issue>
    <description>The POMS Standard form contains 65 items (0-232). The respondent rates each item on a 5-point scale, ranging from &quot;Not at all (0)&quot; to &quot;Extremely (4).&quot; The assessment measures six identified mood factors:
Tension-Anxiety
Depression-Dejection
Anger-Hostility
Vigor-Activity
Fatigue-Inertia
Confusion-Bewilderment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at Week 12/Early Withdrawal (EW) in Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>Baseline - Week 12/EW</time_frame>
    <safety_issue>No</safety_issue>
    <description>Self screening questionnaire that requires the first response to questions. Questionnaire consists of 14 questions, seven for anxiety &quot;0-21&quot; and seven for depression &quot;0-21&quot;. Questions are answered on a four point scale from 0-3; Items 1, 3, 5, 6, 8, 10, 11, and 13 are reversed for summation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Analysis: Plasma Concentrations of SK&amp;F101468, an Unchanged Form of Ropinirole.</measure>
    <time_frame>Weeks 1-12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma samples taken at 24 hours after dosing had been administered for 3 days or longer. This was repeated if the dose was escalated. Lower Limits of Quantitation (LLQ) for SK&amp;101468 = 20 pg/mL. The lowest concentration of analyte can be measured with established acceptable accuracy and precision.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Analysis: Plasma Concentrations of SK&amp;F104557, a Circulating Metabolite of Ropinirole.</measure>
    <time_frame>Weeks 1 -12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma samples taken at 24 hours after dosing had been administered for 3 days or longer. This was repeated if the dose was escalated. Lower Limits of Quantitation (LLQ) for SK&amp;104557 = 20 pg/mL. The lowest concentration of analyte can be measured with established acceptable accuracy and precision.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Analysis: Plasma Concentrations of SK&amp;F89124, a Circulating Metabolite of Ropinirole.</measure>
    <time_frame>Weeks 1-12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma samples taken at 24 hours after dosing had been administered for 3 days or longer. This was repeated if the dose was escalated. Lower Limits of Quantitation (LLQ) for SK&amp;89124 = 20 pg/mL. The lowest concentration of analyte can be measured with established acceptable accuracy and precision.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Restless Legs Syndrome</condition>
  <arm_group>
    <arm_group_label>ropinirole CR-RLS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will orally take ropinirole CR-RLS tablet(s) once daily 1-2 hours before the onset of RLS symptoms at about the same time of the day. The time of taking ropinirole must be after 16:00.Adjustment of the Ropinirole CR-RLS tablets should be completed after the Week 1 visit up to the Week 10 visit. The dose will be increased at intervals of at least one week until sufficient efficacy is obtained (use &quot;much improved&quot; as a guide) without safety problem. Dose escalation will start at the initial dose 0.5 mg/day to 1 mg/day; after 1 mg/day, the dose will be increased by 1 mg/day to the maximum 6 mg/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ropinirole controlled release (CR)-RLS</intervention_name>
    <description>White film-coated round-shaped tablet</description>
    <arm_group_label>ropinirole CR-RLS</arm_group_label>
    <other_name>Ropinirole CR-RLS (SK&amp;F101468)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A subject will be considered eligible for inclusion in this study only if all of the
             following criteria apply:

        At Week -1 (at the start of Screening period)

          -  Patients who are diagnosed with RLS according to the International RLS Study Group's
             (IRLSSG) Diagnostic Criteria.

          -  Age: Patients aged at least 18 years and under 80 years.

          -  Patients who have had RLS symptoms in the evening or nighttime (17:00 to 7:00 next
             day) for at least 20 days within one month before the start of the screening period.
             Patients treated for RLS before the start of the Screening period and who do not meet
             this criterion are considered eligible if the previous therapy can be discontinued
             from the Screening period.

          -  Patients who experience RLS symptoms requiring treatment after 17:00 but prior to
             bedtime.

          -  Gender: male and female Female of child-bearing potential will be eligible for
             inclusion in this study. However they must have a negative pregnancy test at the
             Screening visit. They agree are perform pregnancy test at the time determined and
             practice one of the following method of contraception from the Screening visit till
             the end of follow-up examination.

               -  Abstinence

               -  Oral Contraceptive, either combined or progestogen alone

               -  Injectable progestogen

               -  Implants of levonorgestrel

               -  Estrogenic vaginal ring

               -  Percutaneous contraceptive patches

               -  Intrauterine device (IUD) or intrauterine system (IUS) that meets the SOP
                  effectiveness criteria as stated in the product label

               -  Male partner sterilization (vasectomy with documentation of azoospermia) prior
                  to the female subject's entry into the study, and this male is the sole partner
                  for that subject

               -  Double barrier method: condom or occlusive cap (diaphragm or cervical / vault
                  caps) plus spermicidal agent (foam /gel / film / cream / suppository

          -  Inpatient or outpatient status: Outpatient status

          -  Patients who are able to give informed written consent in person. For patients aged
             under 20 years, their legally acceptable representatives are able to give informed
             written consent.

        At Week 0 (at the start of treatment period)

          -  Patients who experience RLS symptoms in the evening and nighttime (17:00 to 7:00 next
             day) for at least 4 days within 7 days before the start of the treatment period.

          -  Patients who have sleep impairment associated with RLS. Patients who answered as 3
             (severe) or 4 (very severe) to Question 4 (Sleep disturbance) in the IRLS Rating
             Scale

          -  Patients whose IRLS Rating Scale total scores are 15 points or more.

        Exclusion Criteria:

          -  Patients requiring treatment for daytime RLS symptoms (7:00 to 17:00).

          -  Patients with signs of secondary RLS (e.g. chronic renal failure, iron-deficiency
             anemia, pregnancy, rheumatoid arthritis and Parkinson's disease).

          -  Patients whose serum ferritin level is &lt;10 μg/L (ng/mL) at the start of Screening
             period.

          -  Patients with following sleep disorder not associated with RLS e.g. narcolepsy, sleep
             terror disorder, sleep walking disorder, breathing related sleep disorder (Patients
             with obvious apnea in nighttime sleeping when they do not have alcohol drinking or
             over 15 times/hour is used to a target for apnea hypopnea index,in which case to
             implement polysomnography), etc.

          -  Patients with complication of movement disorder (e.g. Parkinson's disease,
             dyskinesia, dystonia, etc.).

          -  Patients with severe hepatic/renal/cardiac/pulmonary disorder or hematopoietic
             disorder.

        The severity refers to Grade 3 according to &quot;the Classification of the Severity of Adverse
        Experiences&quot; (Pharmaceutical affairs Bureau/Safety Division (PAB/SD) Notification No. 80,
        dated 29 June 1992).

          -  Patients with the medical history or complication of cancer or malignant tumour.

          -  Patients with the medical history or complication of substance abuse (e.g. alcohol or
             drug) or dependency of substance for the last one year

          -  Patients whose diastolic blood pressure (BP) is &gt;110 mmHg or &lt;50 mmHg or whose
             systolic BP is &gt;180 mmHg or &lt;90 mmHg at the start of Screening period and Week0.

          -  Patients intolerant for ropinirole hydrochloride (HCl) or other dopamine agonists.

          -  Patients with the medical history of allergy to ropinirole HCl in the past.

          -  Patients with the medical history of Augmentation to ropinirole HCl or other dopamine
             agonists in the past and those who have experienced early morning RLS symptoms.

        Augmentation is defined as below:

        RLS appear 2 hours earlier than the pre-treatment. Symptoms become severer than the
        pre-treatment. Symptoms which start after less time at rest than they did before
        treatment. The RLS extend to other sites (e.g. arm and trunk).

          -  Patients without nighttime sleeping habit (e.g. night-shift worker, etc.) and those
             who must drastically change the habitual bedtime during the study duration.

          -  Patients who have participated in another clinical study of an investigational
             product or medical device within the last 12 weeks prior to the start of screening
             period.

          -  Female patients who are pregnant or lactating, who may be pregnant, or who plan for
             pregnancy during the study .

          -  Patients with chronic hepatitis typeB and /or typeC which is positive of hepatitis B
             surface antigen （HBsAg）and/or hepatitis C antibody.

          -  Patients who have medical conditions which, in the opinion of investigator could
             affect efficacy and safety assessment. This may include, but are not limited to the
             following disorders: diabetes, peripheral neuropathy, fibromyalgia syndrome,
             symptomatic orthostatic hypotension, hepatic or renal failure, pleuro-pulmonary
             fibrosis.

          -  Patients who have received treatment of an estrogen drug product and a drug that are
             known to substantially inhibit CYP1A2 and have changed the dose from baseline visit
             to Week 0.

          -  Others whom the investigator (sub investigator) considers ineligible for the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <reference>
    <citation>GSK has concluded that it is not feasible to publish this study in a peer-reviewed scientific journal because the nature of the study is unlikely to be of interest to a journal. GSK is providing the attached study results summary with a conclusion.</citation>
  </reference>
  <verification_date>March 2011</verification_date>
  <lastchanged_date>April 11, 2013</lastchanged_date>
  <firstreceived_date>September 14, 2007</firstreceived_date>
  <firstreceived_results_date>February 2, 2009</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RLS</keyword>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ropinirole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ropinirole CR-RLS</title>
          <description>Subjects who took oral Ropinirole CR-RLS once daily 1-2 hours before onset of Restless Legs Syndrome (RLS) symptoms (after 4pm). Initial dose level was 0.5 mg/day and increased weekly by 1 mg/day until sufficient efficacy was obtained without any tolerability issues. Treatment period was 12 weeks. Maximum dose level was 6 mg per day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ropinirole CR-RLS</title>
          <description>Subjects who took oral Ropinirole CR-RLS once daily 1-2 hours before onset of Restless Legs Syndrome (RLS) symptoms (after 4pm). Initial dose level was 0.5 mg/day and increased weekly by 1 mg/day until sufficient efficacy was obtained without any tolerability issues. Treatment period was 12 weeks. Maximum dose level was 6 mg per day.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="35"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="48.2" spread="14.7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Number of participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Number of participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Japan</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="35"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Drug Related Adverse Events-On-Therapy</title>
        <time_frame>Weeks 1 - 12 Treatment Period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population consisting of the subjects who took at least one dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Ropinirole CR-RLS</title>
            <description>Subjects who took oral Ropinirole CR-RLS once daily 1-2 hours before onset of Restless Legs Syndrome (RLS) symptoms (after 4pm). Initial dose level was 0.5 mg/day and increased weekly by 1 mg/day until sufficient efficacy was obtained without any tolerability issues. Treatment period was 12 weeks. Maximum dose level was 6 mg per day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Drug Related Adverse Events-On-Therapy</title>
            <units>Number of Events</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Subjects with any Adverse Events</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nausea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Somnolence</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vomiting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypersomnia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dizziness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dyspepsia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Stomach discomfort</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Abdominal pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anemia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Insomnia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Irritability</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Malaise</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Middle Insomnia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Motion Sickness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Palpitations</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Thirst</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in International Restless Leg Syndrome (IRLS) Rating Scale Total Score</title>
        <description>The IRLS Scale assesses the severity of sensory and motor symptoms, sleep disturbance, daytime somnolence, and impact on activities of daily living and mood. The questionnaire scores various questions and totals them using the following scale: Very severe=31-40 points, Severe=21-30 points, Moderate=11-20 points, Mild=1-10 points, None=0 points.</description>
        <time_frame>Baseline and after Week 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set: Subjects entered to the treatment period, except for those not fulfilling the major registration criteria, those who did not take even one dose of the study medication, and those for whom no observation data were available after starting the study treatment. Method for missing data is Last Observation Carried Forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Ropinirole CR-RLS</title>
            <description>Subjects who took oral Ropinirole CR-RLS once daily 1-2 hours before onset of Restless Legs Syndrome (RLS) symptoms (after 4pm). Initial dose level was 0.5 mg/day and increased weekly by 1 mg/day until sufficient efficacy was obtained without any tolerability issues. Treatment period was 12 weeks. Maximum dose level was 6 mg per day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline to Week 12 in International Restless Leg Syndrome (IRLS) Rating Scale Total Score</title>
            <description>The IRLS Scale assesses the severity of sensory and motor symptoms, sleep disturbance, daytime somnolence, and impact on activities of daily living and mood. The questionnaire scores various questions and totals them using the following scale: Very severe=31-40 points, Severe=21-30 points, Moderate=11-20 points, Mild=1-10 points, None=0 points.</description>
            <units>Points on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>IRLS assessment Score - week 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25.3" spread="4.42"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IRLS assessment Score - week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.0" spread="7.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline at week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-19.3" spread="7.68"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression Scale - Severity of Illness (CGI-S)</title>
        <description>The CGI-S scale measures the overall severity of illness on a 7 point scale. Normal = 1, Borderline = 2, Mildly = 3, Moderately = 4, Markedly = 5, Severely = 6, Extremely Severe = 7(no subjects scored a 7).</description>
        <time_frame>Baseline - Final assessment point</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set Population (Baseline, Weeks 1, 2, 3, 4 = 35 subjects; Weeks 5 and 6 = 33 subjects; Week 8 = 32 subjects; Weeks 10 and 12 = 30 subjects; Final assessment point = 35 subjects). Method of Missing Data = LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Ropinirole CR-RLS</title>
            <description>Subjects who took oral Ropinirole CR-RLS once daily 1-2 hours before onset of Restless Legs Syndrome (RLS) symptoms (after 4pm). Initial dose level was 0.5 mg/day and increased weekly by 1 mg/day until sufficient efficacy was obtained without any tolerability issues. Treatment period was 12 weeks. Maximum dose level was 6 mg per day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clinical Global Impression Scale - Severity of Illness (CGI-S)</title>
            <description>The CGI-S scale measures the overall severity of illness on a 7 point scale. Normal = 1, Borderline = 2, Mildly = 3, Moderately = 4, Markedly = 5, Severely = 6, Extremely Severe = 7(no subjects scored a 7).</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Baseline - Normal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline - Borderline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline - Mildly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline - Moderately</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline - Markedly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline - Severely</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 1 - Normal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 1 - Borderline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 1 - Mildly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 1 - Moderately</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 1 - Markedly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 1 - Severely</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 2 - Normal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 2 - Borderline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 2 - Mildly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 2 - Moderately</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 2 - Markedly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 2 - Severely</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 3 - Normal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 3 - Borderline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 3 - Mildly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 3 - Moderately</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 3 - Markedly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 3 - Severely</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4 - Normal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4 - Borderline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4 - Mildly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4 - Moderately</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4 - Markedly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4 - Severely</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 5 - Normal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 5 - Borderline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 5 - Mildly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 5 - Moderately</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 5 - Markedly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 5 - Severely</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 6 - Normal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 6 - Borderline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 6 - Mildly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 6 - Moderately</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 6 - Markedly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 6 - Severely</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 8 - Normal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 8 - Borderline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 8 - Mildly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 8 - Moderately</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 8 - Markedly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 8 - Severely</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 10 - Normal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 10 - Borderline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 10 - Mildly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 10 - Moderately</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 10 - Markedly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 10 - Severely</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12 - Normal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12 - Borderline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12 - Mildly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12 - Moderately</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12 - Markedly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12 - Severely</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final assessment point - Normal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final assessment point - Borderline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final assessment point - Mildly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final assessment point - Moderately</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final assessment point - Markedly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final assessment point - Severely</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression Global Improvement (CGI-GI)</title>
        <description>CGI-GI is a 7 point scale assessing Global Improvement. 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse (no patients scored a 5, 6, or 7).</description>
        <time_frame>Baseline - Final assessment point</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set Population (Weeks 1, 2, 3, and 4 = 35 subjects; Weeks 5 and 6 = 33 subjects; Week 8 = 32 subjects; Week 10, 12 = 30 subjects; Final assessment point = 35 subjects). Method for missing date is LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Ropinirole CR-RLS</title>
            <description>Subjects who took oral Ropinirole CR-RLS once daily 1-2 hours before onset of Restless Legs Syndrome (RLS) symptoms (after 4pm). Initial dose level was 0.5 mg/day and increased weekly by 1 mg/day until sufficient efficacy was obtained without any tolerability issues. Treatment period was 12 weeks. Maximum dose level was 6 mg per day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clinical Global Impression Global Improvement (CGI-GI)</title>
            <description>CGI-GI is a 7 point scale assessing Global Improvement. 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse (no patients scored a 5, 6, or 7).</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Week 1 - Very Much Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 1 - Much Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 1 - Minimally Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 1 - No Change</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 2 - Very Much Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 2 - Much Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 2 - Minimally Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 2 - No Change</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 3 - Very Much Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 3 - Much Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 3 - Minimally Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 3 - No Change</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4 - Very Much Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4 - Much Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4 - Minimally Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4 - No Change</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 5 - Very Much Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 5 - Much Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 5 - Minimally Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 5 - No Change</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 6 - Very Much Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 6 - Much Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 6 - Minimally Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 6 - No Change</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 8 - Very Much Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 8 - Much Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 8 - Minimally Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 8 - No Change</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 10 - Very Much Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 10 - Much Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 10 - Minimally Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 10 - No Change</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12 - Very Much Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12 - Much Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12 - Minimally Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12 - No Change</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final assessment point - Very Much Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final assessment point - Much Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final assessment point - Minimally Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final assessment point - No Change</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at Week 12/Early Withdrawal (EW) in Pittsburgh Sleep Quality Index (PSQI) Total Score</title>
        <description>The PSQI generates seven scores that correspond to different domains. Each component score ranges from 0 (no difficulty) to 3 (severe difficulty). The domain scores are totaled to produce a global score (range of 0–21). A PSQI global score &gt; 5 is considered to be suggestive of significant sleep disturbance.</description>
        <time_frame>Baseline - Week 12/EW</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set(FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Ropinirole CR-RLS</title>
            <description>Subjects who took oral Ropinirole CR-RLS once daily 1-2 hours before onset of Restless Legs Syndrome (RLS) symptoms (after 4pm). Initial dose level was 0.5 mg/day and increased weekly by 1 mg/day until sufficient efficacy was obtained without any tolerability issues. Treatment period was 12 weeks. Maximum dose level was 6 mg per day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline at Week 12/Early Withdrawal (EW) in Pittsburgh Sleep Quality Index (PSQI) Total Score</title>
            <description>The PSQI generates seven scores that correspond to different domains. Each component score ranges from 0 (no difficulty) to 3 (severe difficulty). The domain scores are totaled to produce a global score (range of 0–21). A PSQI global score &gt; 5 is considered to be suggestive of significant sleep disturbance.</description>
            <units>Points on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>PSQI Total Score at Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.4" spread="3.20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PSQI Total Score at Week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.4" spread="2.89"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline at Week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-4.2" spread="3.94"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12/EW in Pittsburgh Sleep Quality Index (PSQI) Total Score by Domains</title>
        <description>The PSQI generates seven scores that correspond to different domains. Each component score ranges from 0 (no difficulty) to 3 (severe difficulty). The domain scores are totaled to produce a global score (range of 0–21). A PSQI global score &gt; 5 is considered to be suggestive of significant sleep disturbance.</description>
        <time_frame>Baseline - Week 12/EW</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set(FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Ropinirole CR-RLS</title>
            <description>Subjects who took oral Ropinirole CR-RLS once daily 1-2 hours before onset of Restless Legs Syndrome (RLS) symptoms (after 4pm). Initial dose level was 0.5 mg/day and increased weekly by 1 mg/day until sufficient efficacy was obtained without any tolerability issues. Treatment period was 12 weeks. Maximum dose level was 6 mg per day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline to Week 12/EW in Pittsburgh Sleep Quality Index (PSQI) Total Score by Domains</title>
            <description>The PSQI generates seven scores that correspond to different domains. Each component score ranges from 0 (no difficulty) to 3 (severe difficulty). The domain scores are totaled to produce a global score (range of 0–21). A PSQI global score &gt; 5 is considered to be suggestive of significant sleep disturbance.</description>
            <units>Points on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Sleep Quality - Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" spread="0.62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sleep Quality - Week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.2" spread="0.77"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sleep Quality - Change from Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.9" spread="0.78"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Duration getting to sleep - Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" spread="1.04"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Duration getting to sleep - Week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" spread="0.88"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Duration getting to sleep - Change from Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.1" spread="1.09"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sleep Duration - Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.9" spread="0.77"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sleep Duration - Week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.5" spread="0.79"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sleep Duration - Change from Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.4" spread="0.74"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sleep Adequacy - Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.9" spread="1.11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sleep Adequacy - Week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.4" spread="0.70"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sleep Adequacy - Change from Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.6" spread="1.19"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sleep Disturbance - Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.2" spread="0.43"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sleep Disturbance - Week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.9" spread="0.55"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sleep Disturbance - Change from Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.3" spread="0.60"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Use of Sleeping pill - Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.4" spread="1.01"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Use of Sleeping pill - Week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.0" spread="0.00"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Use of Sleeping pill - Change from Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.4" spread="1.03"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Somnolence - Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" spread="0.92"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Somnolence - Week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.5" spread="0.62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Somnolence - Change from Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.5" spread="0.97"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at Week 12/Early Withdrawal (EW) in Johns Hopkins Restless Leg Syndrome Quality of Life Questionnaire (RLSQOL) on the Overall Life Impact Score</title>
        <description>The RLSQOL scale consists of 18 items, 13 of which are scored on a 5-point scale. Ten of the items can be summed to the overall life impact score, which can be transformed to a 0-100 score. Mild = 84.48, Moderate = 62.93, or Severe = 37.47</description>
        <time_frame>Baseline and Week 12/EW</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set(FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Ropinirole CR-RLS</title>
            <description>Subjects who took oral Ropinirole CR-RLS once daily 1-2 hours before onset of Restless Legs Syndrome (RLS) symptoms (after 4pm). Initial dose level was 0.5 mg/day and increased weekly by 1 mg/day until sufficient efficacy was obtained without any tolerability issues. Treatment period was 12 weeks. Maximum dose level was 6 mg per day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline at Week 12/Early Withdrawal (EW) in Johns Hopkins Restless Leg Syndrome Quality of Life Questionnaire (RLSQOL) on the Overall Life Impact Score</title>
            <description>The RLSQOL scale consists of 18 items, 13 of which are scored on a 5-point scale. Ten of the items can be summed to the overall life impact score, which can be transformed to a 0-100 score. Mild = 84.48, Moderate = 62.93, or Severe = 37.47</description>
            <units>Points on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>RLSQOL Overall Life Impact Score - Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="65.29" spread="14.499"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RLSQOL Overall Life Impact Score - Week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="89.09" spread="13.431"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23.94" spread="16.759"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Haematology Clinical Lab Values Change From Baseline</title>
        <description>Standard units of measure vary. Therefore, Mean Change is represented in Standard Units: Hematocrit = SI unit of GSK; Hemoglobin = G/L; Platelet count, White Blood Cell count = GI/L; Red Blood Cell count = TI/L. n = number of subjects evaluated. EW = Early Withdrawal.</description>
        <time_frame>Baseline - Week 13 (Follow-up)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population (Week 4 = 35 subjects, Week 8 = 32 subjects, Week 12 = 30 subjects, Week 12/EW = 33 subjects, Week 13 (Follow-up) = 35 subjects whose labs were evaluated).</population>
        <group_list>
          <group group_id="O1">
            <title>Ropinirole CR-RLS</title>
            <description>Subjects who took oral Ropinirole CR-RLS once daily 1-2 hours before onset of Restless Legs Syndrome (RLS) symptoms (after 4pm). Initial dose level was 0.5 mg/day and increased weekly by 1 mg/day until sufficient efficacy was obtained without any tolerability issues. Treatment period was 12 weeks. Maximum dose level was 6 mg per day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Haematology Clinical Lab Values Change From Baseline</title>
            <description>Standard units of measure vary. Therefore, Mean Change is represented in Standard Units: Hematocrit = SI unit of GSK; Hemoglobin = G/L; Platelet count, White Blood Cell count = GI/L; Red Blood Cell count = TI/L. n = number of subjects evaluated. EW = Early Withdrawal.</description>
            <units>Varied Standard Units of Measure</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Hemoglobin (G/L) - week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.2" spread="6.97"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hemoglobin (G/L) - week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.7" spread="8.79"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hemoglobin (G/L) - week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.0" spread="4.84"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hemoglobin (G/L) - week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.8" spread="4.69"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hemoglobin (G/L)- week 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.2" spread="7.30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hematocrit (SI) - week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.0033" spread="0.01972"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hematocrit (SI) - week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.0074" spread="0.02470"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hematocrit (SI) - week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.0021" spread="0.01174"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hematocrit (SI) - week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.0016" spread="0.01148"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hematocrit (SI) - week 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.0063" spread="0.01929"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Platelet Count (GI/L) - week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.5" spread="26.86"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Platelet Count (GI/L) - week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.7" spread="27.92"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Platelet Count (GI/L) - week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.5" spread="22.79"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Platelet Count (GI/L) - week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.8" spread="21.74"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Platelet Count (GI/L) - week 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.7" spread="41.48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Red Blood Cell Count (TI/L) - week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.043" spread="0.2139"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Red Blood Cell Count (TI/L) - week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.084" spread="0.2701"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Red Blood Cell Count (TI/L) - week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.015" spread="0.1469"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Red Blood Cell Count (TI/L) - week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.011" spread="0.1411"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Red Blood Cell Count (TI/L) - week 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.050" spread="0.2140"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>White Blood Cell Count (GI/L) - week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.191" spread="1.1655"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>White Blood Cell Count (GI/L) - week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.268" spread="1.8694"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>White Blood Cell Count (GI/L) - week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.577" spread="1.4972"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>White Blood Cell Count (GI/L) - week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.516" spread="1.4407"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>White Blood Cell Count (GI/L) - week 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.624" spread="1.4914"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Chemistry Clinical Lab Values Change From Baseline</title>
        <description>Mean Change in Standard Units of Measure: Albumin, Total Protein=G/L; Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Lactate Dehydrogenase, Creatine Phosphokinase, Gamma Glutamyl Transferase=IU/L; Total Bilirubin, Creatinine=UMOL/L; Blood Urea Nitrogen, Cholesterol, Chloride, Sodium, Potassium=MMOL/L; Prolactin=MCG/L</description>
        <time_frame>Baseline - Week 13 (Follow-up)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population (Week 4 = 35 subjects, Week 8 = 32 subjects, Week 12 = 30 subjects, Week 12/EW = 33 subjects, Week 13 (Follow-up) = 35 subjects whose labs were evaluated).</population>
        <group_list>
          <group group_id="O1">
            <title>Ropinirole CR-RLS</title>
            <description>Subjects who took oral Ropinirole CR-RLS once daily 1-2 hours before onset of Restless Legs Syndrome (RLS) symptoms (after 4pm). Initial dose level was 0.5 mg/day and increased weekly by 1 mg/day until sufficient efficacy was obtained without any tolerability issues. Treatment period was 12 weeks. Maximum dose level was 6 mg per day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Blood Chemistry Clinical Lab Values Change From Baseline</title>
            <description>Mean Change in Standard Units of Measure: Albumin, Total Protein=G/L; Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Lactate Dehydrogenase, Creatine Phosphokinase, Gamma Glutamyl Transferase=IU/L; Total Bilirubin, Creatinine=UMOL/L; Blood Urea Nitrogen, Cholesterol, Chloride, Sodium, Potassium=MMOL/L; Prolactin=MCG/L</description>
            <units>Varied Standard Units of Measure</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Albumin (G/L) - week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.0" spread="2.35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Albumin (G/L) - week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.4" spread="2.64"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Albumin (G/L) - week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.7" spread="2.34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Albumin (G/L) - week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.6" spread="2.28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Albumin (G/L) - week 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.3" spread="2.33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alkaline Phosphatase (IU/L) - week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.2" spread="30.53"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alkaline Phosphatase (IU/L) - week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.2" spread="26.94"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alkaline Phosphatase (IU/L) - week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.2" spread="29.35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alkaline Phosphatase (IU/L) - week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.4" spread="28.52"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alkaline Phosphatase (IU/L) - week 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.0" spread="36.45"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alanine Amino Transferase (IU/L) - week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.3" spread="3.80"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alanine Amino Transferase (IU/L) - week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.7" spread="5.08"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alanine Amino Transferase (IU/L) - week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.7" spread="4.66"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alanine Amino Transferase - week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.8" spread="4.56"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alanine Amino Transferase - week 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4" spread="6.36"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Aspartate Amino Transferase(IU/L) - week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.4" spread="4.55"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Aspartate Amino Transferase (IU/L) - week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.2" spread="4.07"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Aspartate Amino Transferase (IU/L) - week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.3" spread="4.57"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Aspartate Amino Transferase (IU/L) - week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.5" spread="4.51"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Aspartate Amino Transferase (IU/L) - week 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.6" spread="4.35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Bilirubin (UMOL/L) - week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.147" spread="3.1686"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Bilirubin (UMOL/L) - week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.588" spread="2.5180"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Bilirubin (UMOL/L) - week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.513" spread="3.4244"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Bilirubin (UMOL/L) - week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.311" spread="3.3513"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Bilirubin (UMOL/L) - week 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.173" spread="3.7959"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood Urea Nitrogen (MMOL/L) - week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.14382" spread="1.079245"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood Urea Nitrogen (MMOL/L) - week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.06024" spread="0.862798"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood Urea Nitrogen (MMOL/L) - week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.25704" spread="1.076664"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood Urea Nitrogen (MMOL/L) - week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.30399" spread="1.043047"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood Urea Nitrogen (MMOL/L) - week 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.32334" spread="0.974457"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cholesterol (MMOL/L) - week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.093835" spread="0.5322345"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cholesterol (MMOL/L) - week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.190717" spread="0.4337538"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cholesterol (MMOL/L) - week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.151712" spread="0.5674075"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cholesterol (MMOL/L) - week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.146540" spread="0.5494743"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cholesterol - week 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.107873" spread="0.5638668"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chloride(MMOL/L) - week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.1" spread="1.78"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chloride (MMOL/L) - week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.3" spread="2.07"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chloride (MMOL/L) - week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.3" spread="1.81"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chloride (MMOL/L) - week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.2" spread="1.92"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chloride (MMOL/L) - week 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.1" spread="2.30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lactate Dehydrogenase (IU/L) - week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.3" spread="22.02"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lactate Dehydrogenase (IU/L) - week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.3" spread="16.74"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lactate Dehydrogenase (IU/L) - week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" spread="25.96"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lactate Dehydrogenase (IU/L) - week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.7" spread="25.06"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lactate Dehydrogenase (IU/L) - week 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.2" spread="18.78"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sodium (MMOL/L) - week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.4" spread="1.37"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sodium (MMOL/L) - week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.2" spread="1.36"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sodium (MMOL/L) - week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.0" spread="1.11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sodium (MMOL/L) - week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.0" spread="1.07"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sodium (MMOL/L) - week 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.2" spread="1.29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Prolactin (MCG/L) - week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.80" spread="7.003"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Prolactin (MCG/L) - week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.51" spread="7.229"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Prolactin (MCG/L) - week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.20" spread="6.770"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Prolactin (MCG/L) - week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.22" spread="6.466"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Prolactin (MCG/L) - week 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.14" spread="7.144"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Protein (G/L) - week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.1" spread="3.73"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Protein (G/L) - week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.7" spread="4.03"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Protein (G/L) - week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.8" spread="3.32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Protein (G/L) - week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.8" spread="3.20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Protein (G/L) - week 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.2" spread="3.45"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatine Phosphokinase (IU/L) - week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="72.3" spread="533.72"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatine Phosphokinase (IU/L) - week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-15.8" spread="100.86"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatine Phosphokinase (IU/L) - week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.6" spread="115.92"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatine Phosphokinase (IU/L) - week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.2" spread="110.40"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatine Phosphokinase (IU/L) - week 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.9" spread="124.63"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine (UMOL/L) - week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.3134" spread="4.76710"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine (UMOL/L) - week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.5801" spread="7.23972"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine (UMOL/L) - week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0019" spread="4.73343"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine (UMOL/L) - week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0447" spread="4.60113"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine (UMOL/L) - week 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.6417" spread="4.96904"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gamma Glutamyl Transferase (IU/L) - week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.5" spread="17.56"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gamma Glutamyl Transferase (IU/L) - week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.4" spread="11.68"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gamma Glutamyl Transferase (IU/L) - week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.9" spread="14.56"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gamma Glutamyl Transferase (IU/L) - week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.6" spread="14.26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gamma Glutamyl Tranferase (IU/L) - week 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.1" spread="10.10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Potassium (MMOL/L) - week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.07" spread="0.280"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Potassium (MMOL/L) - week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.05" spread="0.363"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Potassium (MMOL/L) - week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.09" spread="0.305"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Potassium (MMOL/L) - week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.10" spread="0.293"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Potassium (MMOL/L) - week 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.06" spread="0.308"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urinalysis Clinical Lab Values</title>
        <description>Dipstick test values: Neg Value, Trace, +1, +2, +3. No subjects tested higher than +3.</description>
        <time_frame>Baseline - Week 13 (Follow-up)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population (Baseline, Week 4 = 35 subjects, Week 8 = 32 subjects, Week 12 = 30 subjects, Week 12/EW = 33 subjects, Week 13 [Follow-up] = 35 subjects evaluated).</population>
        <group_list>
          <group group_id="O1">
            <title>Ropinirole CR-RLS</title>
            <description>Subjects who took oral Ropinirole CR-RLS once daily 1-2 hours before onset of Restless Legs Syndrome (RLS) symptoms (after 4pm). Initial dose level was 0.5 mg/day and increased weekly by 1 mg/day until sufficient efficacy was obtained without any tolerability issues. Treatment period was 12 weeks. Maximum dose level was 6 mg per day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Urinalysis Clinical Lab Values</title>
            <description>Dipstick test values: Neg Value, Trace, +1, +2, +3. No subjects tested higher than +3.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Urine Urobilinogen - Baseline: Neg Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - Baseline: Trace</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - Baseline: +1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - Baseline: +2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - Baseline: +3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - week 4: Neg Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - week 4: Trace</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - week 4: +1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - week 4: +2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - week 4: +3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - week 8: Neg Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - week 8: Trace</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - week 8: +1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - week 8: +2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - week 8: +3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - week 12: Neg Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - week 12: Trace</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - week 12: +1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - week 12: +2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - week 12: +3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - week 12/EW: Neg Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - week 12/EW: Trace</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - week 12/EW: +1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - week 12/EW: +2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - week 12/EW: +3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - week 13: Neg Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - week 13: Trace</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - week 13: +1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - week 13: +2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Urobilinogen - week 13: +3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Baseline: Neg Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Baseline: Trace</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Baseline: +1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Baseline: +2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Baseline: +3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Week 4: Neg Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Week 4: Trace</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Week 4: +1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Week 4: +2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Week 4: +3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Week 8: Neg Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Week 8: Trace</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Week 8: +1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Week 8: +2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Week 8: +3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Week 12: Neg Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Week 12: Trace</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Week 12: +1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Week 12: +2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Week 12: +3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Week 12/EW: Neg Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Week 12/EW: Trace</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Week 12/EW: +1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Week 12/EW: +2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Week 12/EW: +3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Week 13: Neg Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Week 13: Trace</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Week 13: +1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Week 13: +2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein - Week 13: +3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Baseline: Neg Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Baseline: Trace</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Baseline: +1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Baseline: +2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Baseline: +3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Week 4: Neg Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Week 4: Trace</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Week 4: +1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Week 4: +2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Week 4: +3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Week 8: Neg Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Week 8: Trace</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Week 8: +1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Week 8: +2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Week 8: +3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Week 12: Neg Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Week 12: Trace</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Week 12: +1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Week 12: +2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Week 12: +3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Week 12/EW: Neg Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Week 12/EW: Trace</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Week 12/EW: +1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Week 12/EW: +2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Week 12/EW: +3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Week 13: Neg Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Week 13: Trace</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Week 13: +1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Week 13: +2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Occult Blood - Week 13: +3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Baseline: Neg Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Baseline: Trace</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Baseline: +1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Baseline: +2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Baseline: +3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Week 4: Neg Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Week 4: Trace</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Week 4: +1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Week 4: +2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Week 4: +3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Week 8: Neg Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Week 8: Trace</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Week 8: +1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Week 8: +2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Week 8: +3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Week 12: Neg Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Week 12: Trace</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Week 12: +1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Week 12: +2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Week 12: +3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Week 12/EW: Neg Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Week 12/EW: Trace</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Week 12/EW: +1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Week 12/EW: +2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Week 12/EW: +3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Week 13: Neg Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Week 13: Trace</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Week 13: +1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Week 13: +2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose - Week 13: +3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>12-Lead Electrocardiogram (ECG) Findings Transitions From Baseline</title>
        <description>Baseline Finding/Time Period Finding. Abbreviations: N = normal; A = abnormal; CS = clinically significant; NCS = not clinically significant. Options include N/N, N/ANCS, N/ACS, ANCS/N, ANCS/ANCS, ANCS/ACS, ACS/N, ACS/ANCS, and ACS/ACS.</description>
        <time_frame>Baseline, Week 4, 8, 12, 13 (Follow-up)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population - (Baseline = 35 subjects, Week 4 = 33 subjects, Week 8 = 31 subjects, Week 12/EW = 33 subjects and Week 13 [Follow-up] = 35 subjects evaluated).</population>
        <group_list>
          <group group_id="O1">
            <title>Ropinirole CR-RLS</title>
            <description>Subjects who took oral Ropinirole CR-RLS once daily 1-2 hours before onset of Restless Legs Syndrome (RLS) symptoms (after 4pm). Initial dose level was 0.5 mg/day and increased weekly by 1 mg/day until sufficient efficacy was obtained without any tolerability issues. Treatment period was 12 weeks. Maximum dose level was 6 mg per day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>12-Lead Electrocardiogram (ECG) Findings Transitions From Baseline</title>
            <description>Baseline Finding/Time Period Finding. Abbreviations: N = normal; A = abnormal; CS = clinically significant; NCS = not clinically significant. Options include N/N, N/ANCS, N/ACS, ANCS/N, ANCS/ANCS, ANCS/ACS, ACS/N, ACS/ANCS, and ACS/ACS.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Baseline: N; Baseline: N</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: N; Baseline: ANCS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: N; Baseline: ACS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ANCS; Baseline: N</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ANCS; Baseline: ANCS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ANCS; Baseline: ACS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ACS; Baseline: N</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline; ACS; Baseline: ANCS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ACS ; Baseline: ACS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: N; Week 4: N</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: N; Week 4: ANCS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: N; Week 4: ACS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ANCS; Week 4: N</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ANCS; Week 4: ANCS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ANCS; Week 4: ACS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ACS; Week 4: N</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ACS; Week 4: ANCS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ACS; Week 4: ACS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: N; Week 8: N</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: N; Week 8: ANCS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: N; Week 8: ACS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ANCS; Week 8: N</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ANCS; Week 8: ANCS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ANCS; Week 8: ACS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ACS; Week 8: N</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ACS; Week 8: ANCS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ACS; Week 8: ACS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: N; Week 12/EW: N</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: N; Week 12/EW: ANCS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: N; Week 12/EW: ACS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ANCS; Week 12/EW: N</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ANCS; Week 12/EW: ANCS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ANCS; Week 12/EW: ACS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ACS; Week 12/EW: N</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ACS; Week 12/EW: ANCS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ACS; Week 12/EW: ACS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: N; Week 13: N</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: N; Week 13: ANCS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: N; Week 13: ACS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ANCS; Week 13: N</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ANCS; Week 13: ANCS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ANCS; Week 13: ACS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ACS; Week 13: N</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ACS; Week 13: ANCS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: ACS; Week 13: ACS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vital Signs and Body Weight Change From Baseline</title>
        <description>Units of Measure Vary: Weight = kg; Semi-supine and Standing Systolic and Diastolic BP = mmHg; Semi-supine and Standing Pulse Rate = bpm; EW = early withdrawal; Semi-supine = lying down; Orthostatic = lying, sitting, and standing.</description>
        <time_frame>Baseline to Week 12/EW</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ropinirole CR-RLS</title>
            <description>Subjects who took oral Ropinirole CR-RLS once daily 1-2 hours before onset of Restless Legs Syndrome (RLS) symptoms (after 4pm). Initial dose level was 0.5 mg/day and increased weekly by 1 mg/day until sufficient efficacy was obtained without any tolerability issues. Treatment period was 12 weeks. Maximum dose level was 6 mg per day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Vital Signs and Body Weight Change From Baseline</title>
            <description>Units of Measure Vary: Weight = kg; Semi-supine and Standing Systolic and Diastolic BP = mmHg; Semi-supine and Standing Pulse Rate = bpm; EW = early withdrawal; Semi-supine = lying down; Orthostatic = lying, sitting, and standing.</description>
            <units>Varied Standard Units of Measure</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Weight (Kg)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.5" spread="1.33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Semi-Supine Systolic BP (mmHg)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.7" spread="10.68"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Semi-Supine Diastolic BP (mmHg)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.6" spread="7.25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Semi-Supine Pulse Rate (bpm)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.8" spread="9.11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Standing Systolic BP (mmHg)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.7" spread="10.86"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Standing Diastolic BP (mmHg)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.8" spread="7.64"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Standing Pulse Rate (bpm)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.1" spread="9.94"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Orthostatic Systolic BP (mmHg)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.5" spread="8.50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Orthostatic Diastolic BP (mmHg)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.3" spread="5.58"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Orthostatic Pulse Rate (bpm)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.2" spread="9.15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at Week 12/Early Withdrawal (EW) in Profile of Mood Status (POMS)</title>
        <description>The POMS Standard form contains 65 items (0-232). The respondent rates each item on a 5-point scale, ranging from &quot;Not at all (0)&quot; to &quot;Extremely (4).&quot; The assessment measures six identified mood factors:
Tension-Anxiety
Depression-Dejection
Anger-Hostility
Vigor-Activity
Fatigue-Inertia
Confusion-Bewilderment</description>
        <time_frame>Baseline and Week 12/EW</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ropinirole CR-RLS</title>
            <description>Subjects who took oral Ropinirole CR-RLS once daily 1-2 hours before onset of Restless Legs Syndrome (RLS) symptoms (after 4pm). Initial dose level was 0.5 mg/day and increased weekly by 1 mg/day until sufficient efficacy was obtained without any tolerability issues. Treatment period was 12 weeks. Maximum dose level was 6 mg per day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline at Week 12/Early Withdrawal (EW) in Profile of Mood Status (POMS)</title>
            <description>The POMS Standard form contains 65 items (0-232). The respondent rates each item on a 5-point scale, ranging from &quot;Not at all (0)&quot; to &quot;Extremely (4).&quot; The assessment measures six identified mood factors:
Tension-Anxiety
Depression-Dejection
Anger-Hostility
Vigor-Activity
Fatigue-Inertia
Confusion-Bewilderment</description>
            <units>Points on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>POMS - Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="59.2" spread="21.59"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>POMS - Week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48.0" spread="18.69"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-10.4" spread="14.46"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at Week 12/Early Withdrawal (EW) in Hospital Anxiety and Depression Scale (HADS)</title>
        <description>Self screening questionnaire that requires the first response to questions. Questionnaire consists of 14 questions, seven for anxiety &quot;0-21&quot; and seven for depression &quot;0-21&quot;. Questions are answered on a four point scale from 0-3; Items 1, 3, 5, 6, 8, 10, 11, and 13 are reversed for summation.</description>
        <time_frame>Baseline - Week 12/EW</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS: Subpopulation: HADS Anxiety population, N = 15; HADS Depression population, N = 31. Patients in the FAS population who also have a baseline anxiety domain score of 8 or greater and patients with a baseline depression domain score of 8 or greater will be included in the HADS Anxiety Population and the HADS Depression Population, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Ropinirole CR-RLS</title>
            <description>Subjects who took oral Ropinirole CR-RLS once daily 1-2 hours before onset of Restless Legs Syndrome (RLS) symptoms (after 4pm). Initial dose level was 0.5 mg/day and increased weekly by 1 mg/day until sufficient efficacy was obtained without any tolerability issues. Treatment period was 12 weeks. Maximum dose level was 6 mg per day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline at Week 12/Early Withdrawal (EW) in Hospital Anxiety and Depression Scale (HADS)</title>
            <description>Self screening questionnaire that requires the first response to questions. Questionnaire consists of 14 questions, seven for anxiety &quot;0-21&quot; and seven for depression &quot;0-21&quot;. Questions are answered on a four point scale from 0-3; Items 1, 3, 5, 6, 8, 10, 11, and 13 are reversed for summation.</description>
            <units>Points on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Anxiety-HADS Anxiety Population - Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.3" spread="1.50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anxiety-HADS Anxiety Population - Week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.7" spread="2.39"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline for Anxiety Population</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.8" spread="2.58"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Depression-HADS Depression Population -Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.7" spread="1.42"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Depression-HADS Depression Population-Week 12/EW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.5" spread="1.57"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline for Depression Population</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.1" spread="1.77"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Analysis: Plasma Concentrations of SK&amp;F101468, an Unchanged Form of Ropinirole.</title>
        <description>Plasma samples taken at 24 hours after dosing had been administered for 3 days or longer. This was repeated if the dose was escalated. Lower Limits of Quantitation (LLQ) for SK&amp;101468 = 20 pg/mL. The lowest concentration of analyte can be measured with established acceptable accuracy and precision.</description>
        <time_frame>Weeks 1-12</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) Population: subjects who underwent blood sampling for measuring the trough plasma drug concentrations, excluding those who did not fulfill inclusion criteria, those who were considered to affect the evaluation of the PK research due to drug incompliance or other protocol violation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ropinirole CR-RLS</title>
            <description>Subjects who took oral Ropinirole CR-RLS once daily 1-2 hours before onset of Restless Legs Syndrome (RLS) symptoms (after 4pm). Initial dose level was 0.5 mg/day and increased weekly by 1 mg/day until sufficient efficacy was obtained without any tolerability issues. Treatment period was 12 weeks. Maximum dose level was 6 mg per day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pharmacokinetic Analysis: Plasma Concentrations of SK&amp;F101468, an Unchanged Form of Ropinirole.</title>
            <description>Plasma samples taken at 24 hours after dosing had been administered for 3 days or longer. This was repeated if the dose was escalated. Lower Limits of Quantitation (LLQ) for SK&amp;101468 = 20 pg/mL. The lowest concentration of analyte can be measured with established acceptable accuracy and precision.</description>
            <units>picograms/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>35 subjects who received 0.5 mg of Study drug</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="310.01" spread="188.460"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>27subjects who received 1 mg of Study drug</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="500.97" spread="293.344"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>11 subjects who received 2 mg of Study drug</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="968.36" spread="696.327"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>2 subjects who received 3 mg of Study drug</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1294.55" spread="442.861"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>2 subjects who received 4 mg of Study drug</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1198.10" spread="362.463"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Analysis: Plasma Concentrations of SK&amp;F104557, a Circulating Metabolite of Ropinirole.</title>
        <description>Plasma samples taken at 24 hours after dosing had been administered for 3 days or longer. This was repeated if the dose was escalated. Lower Limits of Quantitation (LLQ) for SK&amp;104557 = 20 pg/mL. The lowest concentration of analyte can be measured with established acceptable accuracy and precision.</description>
        <time_frame>Weeks 1 -12</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ropinirole CR-RLS</title>
            <description>Subjects who took oral Ropinirole CR-RLS once daily 1-2 hours before onset of Restless Legs Syndrome (RLS) symptoms (after 4pm). Initial dose level was 0.5 mg/day and increased weekly by 1 mg/day until sufficient efficacy was obtained without any tolerability issues. Treatment period was 12 weeks. Maximum dose level was 6 mg per day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pharmacokinetic Analysis: Plasma Concentrations of SK&amp;F104557, a Circulating Metabolite of Ropinirole.</title>
            <description>Plasma samples taken at 24 hours after dosing had been administered for 3 days or longer. This was repeated if the dose was escalated. Lower Limits of Quantitation (LLQ) for SK&amp;104557 = 20 pg/mL. The lowest concentration of analyte can be measured with established acceptable accuracy and precision.</description>
            <units>picograms/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>35 subjects who received 0.5 mg of Study drug</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="324.65" spread="134.576"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>27 subjects who received 1 mg of Study drug</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="615.91" spread="259.145"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>11 subjects who received 2 mg of Study drug</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1320.31" spread="523.622"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>2 subjects who received 3 mg of Study drug</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1666.65" spread="325.764"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>2 subjects who received 4 mg of Study drug</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2541.95" spread="198.202"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Analysis: Plasma Concentrations of SK&amp;F89124, a Circulating Metabolite of Ropinirole.</title>
        <description>Plasma samples taken at 24 hours after dosing had been administered for 3 days or longer. This was repeated if the dose was escalated. Lower Limits of Quantitation (LLQ) for SK&amp;89124 = 20 pg/mL. The lowest concentration of analyte can be measured with established acceptable accuracy and precision.</description>
        <time_frame>Weeks 1-12</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ropinirole CR-RLS</title>
            <description>Subjects who took oral Ropinirole CR-RLS once daily 1-2 hours before onset of Restless Legs Syndrome (RLS) symptoms (after 4pm). Initial dose level was 0.5 mg/day and increased weekly by 1 mg/day until sufficient efficacy was obtained without any tolerability issues. Treatment period was 12 weeks. Maximum dose level was 6 mg per day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pharmacokinetic Analysis: Plasma Concentrations of SK&amp;F89124, a Circulating Metabolite of Ropinirole.</title>
            <description>Plasma samples taken at 24 hours after dosing had been administered for 3 days or longer. This was repeated if the dose was escalated. Lower Limits of Quantitation (LLQ) for SK&amp;89124 = 20 pg/mL. The lowest concentration of analyte can be measured with established acceptable accuracy and precision.</description>
            <units>picograms/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>2 subjects who received 0.5 mg of Study drug</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22.45" spread="3.465"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>11 subjects who received 1 mg of Study drug</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30.37" spread="10.227"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>11 subjects who received 2 mg of Study drug</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="42.75" spread="17.286"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>2 subjects who received 3 mg of Study drug</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="46.80" spread="8.202"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>2 subjects who received 4 mg of Study drug</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="72.05" spread="2.051"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ropinirole CR-RLS</title>
          <description>Subjects who took oral Ropinirole CR-RLS once daily 1-2 hours before onset of Restless Legs Syndrome (RLS) symptoms (after 4pm). Initial dose level was 0.5 mg/day and increased weekly by 1 mg/day until sufficient efficacy was obtained without any tolerability issues. Treatment period was 12 weeks. Maximum dose level was 6 mg per day.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Motion sickness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Stomach Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Abdominal Pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Local Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Chillblains</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vertebral injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Initial insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Middle insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Upper Respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cold Sweat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Skin tightness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of the multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
